This latest price level reflects a significant downturn for the company, with the stock experiencing a precipitous 1-year change, plummeting by -77.17%. Investors are closely monitoring MRSN as it ...

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock ... Shares @ Avg Price of $3.25/Share ...

Despite a significant drop in Mersana’s stock price, Zelin views this as an exaggerated ... Mersana Therapeutics (MRSN) Company Description: Mersana Therapeutics, Inc. engages in the development ...

The average 1 year target price among brokers that have covered the stock in the last year is $5.57. MRSN has been the topic of a number of recent research reports. Wedbush reaffirmed an ...

Short interest in Mersana Therapeutics Inc (NASDAQ:MRSN) increased during the last ... betting on the decline of Mersana Therapeutics's stock. Short interest data is updated every two weeks.

Additionally, hormone-receptor positive patients should also have received or be ineligible for endocrine therapy. Price Action: MRSN stock is down 36.6% at $0.8245 at last check Friday.